Search

Your search keyword '"Marie R. Vermeiren"' showing total 4 results
Start Over Author "Marie R. Vermeiren"
4 results on '"Marie R. Vermeiren"'

1. The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study

Author

Marie R. Vermeiren, Joost Somsen, Gert Luurtsema, Fransje E. Reesink, Nicolaas A. Verwey, Liesbeth Hempenius, Nelleke Tolboom, Geert Jan Biessels, J. Matthijs Biesbroek, Meike W. Vernooij, Sophie E. M. Veldhuijzen van Zanten, Harro Seelaar, Emma M. Coomans, Charlotte E. Teunissen, Afina W. Lemstra, Argonde C. van Harten, Leonie N. C. Visser, Wiesje M. van der Flier, Elsmarieke van de Giessen, and Rik Ossenkoppele

Subjects
Alzheimer’s disease, Dementia, Tau, Positron emission tomography, Prospective studies, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Background Tau-PET is a diagnostic tool with high sensitivity and specificity for discriminating Alzheimer’s disease (AD) dementia from other neurodegenerative disorders in well-controlled research environments. The role of tau-PET in real-world clinical practice, however, remains to be established. The aim of the TAP-TAU study is therefore to investigate the impact of tau-PET in clinical practice. Methods TAP-TAU is a prospective, longitudinal multi-center study in 300 patients (≥ 50 years old) with mild cognitive impairment or mild dementia across five Dutch memory clinics. Patients are eligible if diagnostic certainty is

Published
2024
Full Text
View/download PDF

2. Survey among experts on the future role of tau‐PET in clinical practice and trials

Author

Marie R. Vermeiren, Ismael L. Calandri, Wiesje M. van derFlier, Elsmarieke van deGiessen, and Rik Ossenkoppele

Subjects
Alzheimer's disease, positron emission tomography, tau, trials, Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
Abstract

Abstract BACKGROUND Recent advancements in Alzheimer's disease (AD) biomarker research and clinical trials prompt reflection on the value and consequently appropriate use of tau positron emission tomography (tau‐PET) in the future. METHODS We conducted an online survey among dementia and PET experts worldwide to investigate the anticipated future role of tau‐PET in clinical practice and trials. RESULTS Two hundred sixty‐eight dementia experts, comprising 143 clinicians and 121 researchers, covering six continents participated. The vast majority (90%) fostered a positive attitude toward the added value of tau‐PET in clinical practice, particularly for staging, diagnosing, monitoring, and prognostication in a cognitively impaired memory clinic population. Experts anticipated an important role for tau‐PET for participant selection (76%–100%) and measuring endpoints (75%–97%), in both anti‐amyloid and anti‐tau drug trials. DISCUSSION Our global survey study shows that dementia experts envision an important role for tau‐PET in the future, both in clinical practice and in drug trials, beyond current guidelines and practices. Highlights Dementia experts envision an important role for tau‐PET in the future. Experts indicate that a tau‐PET scan could influence patient management. Experts anticipate the utility of tau‐PET for participant selection and endpoints in drug trials. There is a gap between the anticipated usefulness of tau‐PET and current clinical practices.

Published
2024
Full Text
View/download PDF

3. Psychological functioning and quality of life in patients with mastocytosis: A cross-sectional study

Author

Marie R, Vermeiren, Leonieke W, Kranenburg, Paul L A, van Daele, Roy, Gerth van Wijk, and Maud A W, Hermans

Subjects
Adult, Cohort Studies, Male, Cross-Sectional Studies, Surveys and Questionnaires, Quality of Life, Humans, Female, Middle Aged, Mastocytosis, Aged
Abstract

Psychological symptoms appear to be frequent among patients with mastocytosis and can significantly affect patient quality of life. However, it remains unclear whether and to which extent this may be the case.To investigate he presence and type of psychological symptoms and quality of life in patients with mastocytosis.In this cross-sectional cohort study of adult patients with mastocytosis, all patients completed the 36-item Short Form Health Survey (SF-36) and the 90-item Symptom Checklist (SCL-90). Results were compared with those of a healthy groups of patients with other diseases (chronic pain and cancer) and healthy populations.Fifty patients were included in the study. Seventy percent had indolent systemic mastocytosis. Patients with mastocytosis scored significantly worse than a healthy norm group on the total SCL-90 and more specifically on the dimensions of depression, somatization, sleeping problems, and inadequacy of acting and thinking. Strikingly, patients with mastocytosis scored similarly to patients with cancer on the SF-36 subdomains of general health perception and vitality. However, no significant difference in the mental health subdomain of the SF-36 was found when compared with a healthy group.In addition to the presence of psychological symptoms, the physical symptoms that are associated with mastocytosis also have a significant impact on the quality of life of patients with this disease. Therefore, correct treatment through symptom control and psychological counseling is necessary.EudraCT Identifier 2015-004604-37.

Published
2019

4. Psychological functioning and quality of life in patients with mastocytosis

Author

Roy Gerth van Wijk, Leonieke W. Kranenburg, M. A. W. Hermans, Paul L A van Daele, and Marie R. Vermeiren

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, business.industry, Immunology, Chronic pain, Disease, medicine.disease, Mental health, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Quality of life, Internal medicine, medicine, Immunology and Allergy, 030212 general & internal medicine, Systemic mastocytosis, business, Somatization, Depression (differential diagnoses), Cohort study
Abstract

Background Psychological symptoms appear to be frequent among patients with mastocytosis and can significantly affect patient quality of life. However, it remains unclear whether and to which extent this may be the case. Objective To investigate he presence and type of psychological symptoms and quality of life in patients with mastocytosis. Methods In this cross-sectional cohort study of adult patients with mastocytosis, all patients completed the 36-item Short Form Health Survey (SF-36) and the 90-item Symptom Checklist (SCL-90). Results were compared with those of a healthy groups of patients with other diseases (chronic pain and cancer) and healthy populations. Results Fifty patients were included in the study. Seventy percent had indolent systemic mastocytosis. Patients with mastocytosis scored significantly worse than a healthy norm group on the total SCL-90 and more specifically on the dimensions of depression, somatization, sleeping problems, and inadequacy of acting and thinking. Strikingly, patients with mastocytosis scored similarly to patients with cancer on the SF-36 subdomains of general health perception and vitality. However, no significant difference in the mental health subdomain of the SF-36 was found when compared with a healthy group. Conclusion In addition to the presence of psychological symptoms, the physical symptoms that are associated with mastocytosis also have a significant impact on the quality of life of patients with this disease. Therefore, correct treatment through symptom control and psychological counseling is necessary. Trial registration EudraCT Identifier 2015-004604-37.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results